(Q34450659)

2 August 2017

1 reference

title

Considerations for optimal iron use for anemia due to chronic kidney disease (English)

1 reference

2 August 2017

Hudson JQ

1

1 reference

2 August 2017

Comstock TJ

series ordinal

2

1 reference

2 August 2017

publication date

1 October 2001

1 reference

2 August 2017

published in

Clinical Therapeutics

1 reference

2 August 2017

volume

23

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

1637-1671

1 reference

The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Hematologic aspects of end-stage renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Effect of human recombinant erythropoietin on anaemia and dialysis efficiency in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Transferrin receptors in the human gastrointestinal tract. Relationship to body iron stores.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Iron kinetics in healthy individuals and in chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

1 reference

7 January 2021

Iron Absorption in Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

A clinical evaluation of serum ferritin as an index of iron stores

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Serum ferritin assay and bone-marrow iron stores in patients on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Detection of functional iron deficiency during erythropoietin treatment: a new approach

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

The laboratory assessment of iron status--an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

THE DIAGNOSIS OF IRON DEFICIENCY ANEMIA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Evaluation of iron status in patients on chronic hemodialysis: relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Factors determining the percentage of hypochromic red blood cells in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Iron deficiency: definition and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

The determination of plasma transferrin receptor as good index of erythropoietic activity in renal anemia and after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Red cell ferritin as a diagnostic tool

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Laboratory diagnosis of iron-deficiency anemia: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Iron status in patients receiving erythropoietin for dialysis-associated anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

A randomized controlled study of iron supplementation in patients treated with erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Intravenous ferric saccharate as an iron supplement in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Clinical pharmacokinetics of iron preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Haemoglobin and serum iron responses to periodic intravenous iron-dextran infusions during maintenance haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Intravenous Iron Dextran in Clinical Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Suspected iron dextran-related adverse drug events in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

The safety of intravenous iron dextran in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Iron management in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Erythropoietin treatment in haemodialysis patients with iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Hepatic iron in dialysed patients given intravenous iron dextran

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980135-1

7 January 2021

10.1016/S0149-2918(01)80135-1

Identifiers

DOI

1 reference

2 August 2017

1 reference